Ayana Pharma Ltd., Report issue

For profit Phase 1
Founded: Jerusalem Israel (2012)

Organization Overview

First Clinical Trial
2018
NCT03681548
First Marketed Drug
2021
doxorubicin (Doxil)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Ayana Pharma Ltd., | AYANA PHARMA LTD

Active Ingredients

Marketed Drugs (1)

doxorubicin (Doxil) (2021)

Drugs in Phase 1 Trials (1)

doxorubicin (Doxil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 1)

Ovarian Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1